• <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
      <b id="1ykh9"><small id="1ykh9"></small></b>
    1. <b id="1ykh9"></b>

      1. <button id="1ykh9"></button>
        <video id="1ykh9"></video>
      2. west china medical publishers
        Author
        • Title
        • Author
        • Keyword
        • Abstract
        Advance search
        Advance search

        Search

        find Author "ZENG Tingting" 3 results
        • Clinical study of adenosine deaminase-based index in the diagnosis of malignant pleural effusion

          ObjectiveTo explore the clinical value of age/pleural fluid adenosine deaminase (age/ADA) ratio and serum lactate dehydrogenase/pleural fluid adenosine deaminase ratio (Cancer Ratio, CR) in the diagnosis of malignant pleural effusions (MPE). MethodsThe study collected 44 patients with MPE and 48 patients with benign pleural effusion (BPE) to compare the differences in age, gender, carcinoembryonic antigen (CEA), age/ADA ratio and CR between the groups. The receiver operating characteristic (ROC) curve of CEA, age/ADA and CR was constructed and the area under the ROC curve (AUC), sensitivity and specificity was calculated to identify the diagnostic performance of the three indicators alone or in combination in MPE. ResultsCEA, age/ADA and CR were significant higher in the MPE group than those in the BPE group (all P<0.05), the AUCs of CEA, age/ADA and CR were 0.768, 0.837 and 0.866, respectively; the sensitivity was 61.36%, 88.64% and 81.82%, the specificity was 85.42%, 75.00%, 83.33%, respectively. The AUCs of CEA combined with age/ADA, CEA combined with CR, age/ADA combined with CR, CEA combined with age/ADA and CR were respectively 0.892, 0.911, 0.837 and 0.907; the sensitivity was 81.82%, 86.36%, 88.64% and 90.91%, the specificity was 79.17%, 79.17%, 75.00% and 77.08%, respectively. ConclusionsAge/ADA and CR demonstrated good diagnostic performance in MPE, moreover, the diagnostic performance can be further improved when combined with the traditional tumor marker CEA, and more research about its diagnostic value is needed in the future.

          Release date: Export PDF Favorites Scan
        • Association of MDM2 Gene Promoter SNP 309 Polymorphism with Leukemia Susceptibility: A Meta-Analysis of Case-Control Studies

          Objective To investigate the association between MDM2 gene promoter SNP 309 polymorphism and leukemia susceptibility. Methods Such databases as Ovid, EBSCO, PubMed, CNKI, CBM, VIP and WanFang Data were searched to collect the case-control studies published from January 1990 to June 2012. According to the inclusion and exclusion criteria, the studies were screened, the data were extracted, and the methodological quality of the included studies was evaluated. Then meta-analysis was conducted using RevMan 5.0 and Stata 10.0 software, the pooled odds ratio (ORs) with 95% confidence interval (CI) were calculated, and the sensitivity and publication bias were evaluated at the same time. Results A total of 9 studies within 8 articles were included, which involved 1 821 cases and 5 642 controls. The results of meta-analysis showed that, the susceptibility of leukemia was increased in the G allele carriers compared with the T allele carriers (OR=1.26, 95%CI 1.08 to 1.46, P=0.003), and the leukemia risk was higher in the GG genotype populations compared with the TT genotype populations (OR=1.46, 95%CI 1.02 to 2.10, P=0.04). Among Asians with recessive models, the leukemia risk was higher in the homozygous GG genotype compared with both the heterozygous GT genotype and the homozygous TT genotype (OR=2.00, 95%CI 1.37 to 2.92, P=0.000 3). There was no obvious publication bias. Conclusion MDM2 gene promoter SNP 309 polymorphism is associated with the susceptibility of leukemia, and the G allele is likely to be the risk factor for leukemia.

          Release date: Export PDF Favorites Scan
        • Establishment of the Orientation Tube Panel for 8-color Flow Cytometric Immunophenotyping for Patients with Acute Leukemia

          目的 建立急性白血病(AL)患者八色流式免疫表型分析起始管方案。 方法 用胞膜CD3(CD3)、CD19、CD10、CD34、CD45、胞漿CD79a(cCD79a)、髓過氧化物酶(MPO)和胞漿CD3(cCD3)等8種抗體建立八色流式染色方案。膜表面抗體直接染色;膜內抗體經固定破膜,再染色后上機檢測。將3個血小板減少患者骨髓標本分別進行抗體的單色染色和缺一色染色;最后對17例確診的AL初發患者標本進行檢測。 結果 用單色染色來確定染色方案中各抗體的檢測電壓及熒光補償;缺一色染色中,陽性細胞群較單色染色變化均<10%,表明方案中的各抗體相互作用小。17例AL初發患者中,6例急性B淋巴細胞白血病原始細胞均為CD34和CD19陽性,5例cCD79a陽性和4例CD10陽性;4例急性T淋巴細胞白血病患者均為cCD3陽性;6例急性髓細胞白血病均為CD34和MPO陽性;1例B+T混合表型AL患者CD34、cCD3、CD19、cCD79a及CD10均為陽性,MPO和CD3為陰性,此檢測方案能夠確定各類AL的細胞類型。 結論 建立了AL患者八色流式免疫表型分析起始管方案,操作簡便快速,適用于臨床檢測。

          Release date:2016-09-08 09:13 Export PDF Favorites Scan
        1 pages Previous 1 Next

        Format

        Content

      3. <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
          <b id="1ykh9"><small id="1ykh9"></small></b>
        1. <b id="1ykh9"></b>

          1. <button id="1ykh9"></button>
            <video id="1ykh9"></video>
          2. 射丝袜